Study of GPX-100 in the Treatment of Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this early Phase II multicenter trial is to determine the objective clinical
response to GPX-100, an anthracycline similar to doxorubicin, in up to 40 patients with newly
diagnosed metastatic breast cancer. GPX-100 is unique among anthracyclines because it is not
converted to doxorubicinol during metabolism in the body. This metabolite has been shown to
be a major cause of damage to the heart (cardiotoxicity) in laboratory studies. Eligible
patients who are enrolled in this study will receive GPX-100 as a single agent at the
beginning of as many as 8 three week long cycles of chemotherapy. Objective measurements of
tumor response will be made by computed tomography (CT) scans.